The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma

doi:10.1016/j.biomaterials.2008.09.014

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物制剂研究中心

	The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma
	Xu, Zhenghong; Chen, Lingli; Gu, Wangwen; Gao, Yu; Lin, Liping; Zhang, Zhiwen; Xi, Yong; Li, Yaping
刊名	BIOMATERIALS
	2009-01
卷号	30 期号:2 页码:226-232
关键词	Chemotherapy Cytotoxicity Hepatocellular carcinoma Nanoparticles Docetaxel
ISSN号	0142-9612
DOI	10.1016/j.biomaterials.2008.09.014
文献子类	Article
英文摘要	Human hepatocellular carcinoma (HCC) is one of the major causes of death worldwide. Targeted uptake of therapeutic agent in the cell-, tissue- or disease-specific manner represents a potential technology for the treatment of HCC. A new docetaxel-loaded hepatoma-targeted solid lipid nanoparticle (tSLN) was designed and prepared with galactosylated dioleoylphosphatidyl ethanolamine. The cellular cytotoxicity, cellular uptake, subcellular localization, in vivo toxicity, therapeutic effect, biodistribution and histology of tSLNs were investigated, The tSLNs showed the particle size about 120 nM with encapsulation efficiency > 90%, a low burst effect within the first day and a sustained release for the next 29 days in vitro. Cytotoxicity of tSLNs against hepatocellular carcinoma cell line BEL7402 was superior to Taxotere (R) and non-targeted SLNs (nSLNs). The tSLNs also showed better tolerant and antitumor efficacy in murine model bearing hepatoma compared with Taxotere (R) or nSLNs. The studies on cellular uptake and biodistribution indicated that the better antitumor efficacy of tSLNs was attributed to both the increased accumulation of drug in tumor and more cellular uptake by hepatoma cells. The histology demonstrated that tSLNs had no detrimental effect on both healthy liver and liver with fibrosis. These results implied that this targeted nanocarrier of docetaxel could enhance its antitumor effect in vivo with low systemic toxicity for the treatment of locally advanced and metastatic HCC. (c) 2008 Elsevier Ltd. All rights reserved.
资助项目	The National Basic Research Program of China[2007CB935804] ; The National Basic Research Program of China[2006CB933304] ; National Natural Science Foundation of China[30572259] ; CAS[KJCX2.YW.M02] ; CAS[KSCX1-YW-R-21]
WOS关键词	PHASE-II ; GALACTOSYLATED LIPOSOMES ; ANTICANCER DRUGS ; HEPATOMA-CELLS ; CHEMOTHERAPY ; PACLITAXEL ; CANCER ; RECEPTOR ; PHARMACOKINETICS ; FORMULATION
WOS研究方向	Engineering ; Materials Science
语种	英语
出版者	ELSEVIER SCI LTD
WOS记录号	WOS:000261272100011
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/279350]
专题	药物制剂研究中心
通讯作者	Li, Yaping
作者单位	Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
推荐引用方式 GB/T 7714	Xu, Zhenghong,Chen, Lingli,Gu, Wangwen,et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma[J]. BIOMATERIALS,2009,30(2):226-232.
APA	Xu, Zhenghong.,Chen, Lingli.,Gu, Wangwen.,Gao, Yu.,Lin, Liping.,...&Li, Yaping.(2009).The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma.BIOMATERIALS,30(2),226-232.
MLA	Xu, Zhenghong,et al."The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma".BIOMATERIALS 30.2(2009):226-232.